Tags

Type your tag names separated by a space and hit enter

Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.
Mov Disord. 2006 May; 21(5):654-9.MD

Abstract

Parkinson's disease (PD) patients vary widely in their response to levodopa treatment, and this variation may be partially genetic in origin. We determined whether particular dopamine and opioid receptor polymorphisms were associated with risk of earlier onset of dyskinesia side effects during levodopa therapy. Smoking status was also examined. The 92 subjects were recruited from the movement disorders clinic of a neurology practice associated with a medical school. All were adult-onset PD patients who had been taking levodopa at least 5 years and/or had developed levodopa-induced dyskinesia. Carrying the G-allele of the A118G single nucleotide coding region polymorphism of the mu opioid receptor, as well as a history of never smoking, were independently associated with increased risk of earlier onset of dyskinesia (P=0.05 and 0.02, respectively). One genotype of the D2 dopamine receptor intronic dinucleotide repeat polymorphism (14 repeats/15 repeats, with frequency of 6%) was also associated with earlier dyskinesia (P=0.003). History of smoking has previously been associated with reduced risk of developing PD. Our results suggest that smoking history may also influence the response to levodopa, with contribution comparable to those of individual genes including the mu opioid receptor and D2 dopamine receptor.

Authors+Show Affiliations

Department of Cell Biology, Neurobiology, and Anatomy, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA. judith.strong@uc.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

16435402

Citation

Strong, Judith A., et al. "Genotype and Smoking History Affect Risk of Levodopa-induced Dyskinesias in Parkinson's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 21, no. 5, 2006, pp. 654-9.
Strong JA, Dalvi A, Revilla FJ, et al. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2006;21(5):654-9.
Strong, J. A., Dalvi, A., Revilla, F. J., Sahay, A., Samaha, F. J., Welge, J. A., Gong, J., Gartner, M., Yue, X., & Yu, L. (2006). Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 21(5), 654-9.
Strong JA, et al. Genotype and Smoking History Affect Risk of Levodopa-induced Dyskinesias in Parkinson's Disease. Mov Disord. 2006;21(5):654-9. PubMed PMID: 16435402.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease. AU - Strong,Judith A, AU - Dalvi,Arif, AU - Revilla,Fredy J, AU - Sahay,Alok, AU - Samaha,Frederick J, AU - Welge,Jeffrey A, AU - Gong,Jianhua, AU - Gartner,Maureen, AU - Yue,Xia, AU - Yu,Lei, PY - 2006/1/26/pubmed PY - 2006/10/19/medline PY - 2006/1/26/entrez SP - 654 EP - 9 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 21 IS - 5 N2 - Parkinson's disease (PD) patients vary widely in their response to levodopa treatment, and this variation may be partially genetic in origin. We determined whether particular dopamine and opioid receptor polymorphisms were associated with risk of earlier onset of dyskinesia side effects during levodopa therapy. Smoking status was also examined. The 92 subjects were recruited from the movement disorders clinic of a neurology practice associated with a medical school. All were adult-onset PD patients who had been taking levodopa at least 5 years and/or had developed levodopa-induced dyskinesia. Carrying the G-allele of the A118G single nucleotide coding region polymorphism of the mu opioid receptor, as well as a history of never smoking, were independently associated with increased risk of earlier onset of dyskinesia (P=0.05 and 0.02, respectively). One genotype of the D2 dopamine receptor intronic dinucleotide repeat polymorphism (14 repeats/15 repeats, with frequency of 6%) was also associated with earlier dyskinesia (P=0.003). History of smoking has previously been associated with reduced risk of developing PD. Our results suggest that smoking history may also influence the response to levodopa, with contribution comparable to those of individual genes including the mu opioid receptor and D2 dopamine receptor. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/16435402/Genotype_and_smoking_history_affect_risk_of_levodopa_induced_dyskinesias_in_Parkinson's_disease_ L2 - https://doi.org/10.1002/mds.20785 DB - PRIME DP - Unbound Medicine ER -